RT Journal Article
T1 Anti-Spike antibodies 3 months after SARS-CoV-2 mRNA vaccine booster dose in patients on hemodialysis: the prospective SENCOVAC study.
A1 Quiroga, Borja
A1 Soler, María José
A1 Ortiz, Alberto
A1 Jaravaca Mantecón, Carlos Jesús
A1 Nava Pérez, Nathasha
A1 Serra Martín, Marta
A1 Sato, Yurika
A1 Marin Franco, Antonio José
A1 Pazmiño Zambrano, Diana Flor
A1 Lucena Valverde, Rafael
A1 Ortega Diaz, Mayra
A1 Calderón González, Carmen
A1 Cazorla López, Juan Manuel
A1 Pereira, Mónica
A1 González Parra, Emilio
A1 Sánchez Horrillo, Ana
A1 Sánchez González, Carmen
A1 Toapanta, Néstor
A1 Cigarrán Guldris, Secundino
A1 Sánchez Hernández, Rosa
A1 Pizarro Sánchez, Soledad
A1 Muñiz Rincón, María
A1 Garcia-Fernández, Nuria
A1 Blanco Castro, Natalia
A1 Collantes Mateo, Rocío
A1 Quiroz Morales, Manuel Augusto
A1 Escamilla-Cabrera, Beatriz
A1 Berdud Godoy, Isabel
A1 Gil-Casares Casanova, Beatriz
A1 Leyva, Alba
A1 Rojas, José
A1 Gansevoort, Ron T
A1 de Sequera, Patricia
A1 SENCOVAC collaborative network, 
K1 COVID-19
K1 SARS-CoV-2
K1 booster
K1 hemodialysis
K1 vaccination
AB Patients on hemodialysis are at high-risk for complications derived from coronavirus disease 2019 (COVID-19). The present analysis evaluated the impact of a booster vaccine dose and breakthrough severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections on humoral immunity 3 months after the booster dose. This is a multicentric and prospective study assessing immunoglobulin G anti-Spike antibodies 6 and 9 months after initial SARS-CoV-2 vaccination in patients on hemodialysis that had also received a booster dose before the 6-month assessment (early booster) or between the 6- and 9-month assessments (late booster). The impact of breakthrough infections, type of vaccine, time from the booster and clinical variables were assessed. A total of 711 patients [67% male, median age (range) 67 (20-89) years] were included. Of these, 545 (77%) received an early booster and the rest a late booster. At 6 months, 64 (9%) patients had negative anti-Spike antibody titers (3% of early booster and 29% of late booster patients, P = .001). At 9 months, 91% of patients with 6-month negative response had seroconverted and there were no differences in residual prevalence of negative humoral response between early and late booster patients (0.9% vs 0.6%, P = .693). During follow-up, 35 patients (5%) developed breakthrough SARS-CoV-2 infection. Antibody titers at 9 months were independently associated with mRNA-1273 booster (P = .001), lower time from booster (P = .043) and past breakthrough SARS-CoV-2 infection (P  In hemodialysis patients, higher titers of anti-Spike antibodies at 9 months were associated with mRNA-1273 booster, lower time from booster and past breakthrough SARS-CoV-2 infection.
SN 2048-8505
YR 2022
FD 2022-07-26
LK http://hdl.handle.net/10668/19752
UL http://hdl.handle.net/10668/19752
LA en
DS RISalud
RD Apr 9, 2025